TG Therapeutics (NASDAQ:TGTX) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday.

A number of other research analysts also recently issued reports on TGTX. BidaskClub downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 12th. Zacks Investment Research upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. Finally, HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of TG Therapeutics in a research report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $31.00.

Shares of NASDAQ TGTX traded down $1.25 during midday trading on Monday, reaching $9.50. The stock had a trading volume of 2,616,500 shares, compared to its average volume of 1,227,306. The company has a market capitalization of $913.08 million, a P/E ratio of -4.97 and a beta of 1.16. TG Therapeutics has a twelve month low of $7.25 and a twelve month high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 177.79% and a negative net margin of 97,412.51%. sell-side analysts expect that TG Therapeutics will post -2.19 earnings per share for the current year.

In other news, CFO Sean A. Power sold 47,191 shares of the business’s stock in a transaction that occurred on Tuesday, July 3rd. The shares were sold at an average price of $13.21, for a total value of $623,393.11. Following the transaction, the chief financial officer now owns 473,267 shares in the company, valued at approximately $6,251,857.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.10% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in TGTX. Xact Kapitalforvaltning AB acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $139,000. Quantitative Systematic Strategies LLC acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $146,000. Cubist Systematic Strategies LLC acquired a new position in shares of TG Therapeutics during the 1st quarter valued at $176,000. Birchview Capital LP acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $197,000. Finally, North Star Investment Management Corp. acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $276,000. Institutional investors own 48.99% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Further Reading: Asset Allocation Models, Which is Right For You?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.